9914 Federal Register / Vol. 75, No. 42 / Thursday, March 4, 2010 / Notices 

Center for Outcomes and Evidence, 

Agency for Healthcare Research and 

Quality, (please see contact information 

above). 

Submission Criteria 

The survey development teams are 

interested in instruments and items 

through which cancer patients can 

assess the care they receive from 

providers as well as the providers’ 

communication skill. They are also 

interested in instruments and items 

through which clinicians can assess 

delivered care or communication. In 

addition to survey items and 

instruments, the development teams are 

interested in observational measures 

and their associated scoring systems. 

AHRQ, in collaboration with 

experienced investigators, will evaluate 

all submitted instruments and items. 

Instruments and items may be adopted 

verbatim, in whole or in part, or may be 

modified. AHRQ will assume 

responsibility for the final measure sets 

as well as any future modifications to 

either survey. 

Each voluntary submission should 

include the following related 

descriptive information, to the extent 

that it is available: 

• The name of the instrument (or 

observational measure); 

• Domain(s) or key concepts covered 

in the survey; 

• Language(s) in which the 

instrument is available; 

• Evidence of cultural/cross group 

comparability; 

• Cognitive screening or assessments 

used and cognitive testing results; 

• Method of selection of respondent 

(i.e., patient) or patient representative or 

spokesperson (i.e., most appropriate 

family member/significant other, if more 

than one available); 

• Response rates; 

• Cost estimates for data collection; 

• Instrument reliability (internal 

consistency, test-retest, etc.); 

• Validity (content, construct, 

criterion-related); 

• Methods and results of field-testing; 

and, 

• Description of sampling strategies 

and data collection protocols, including 

such elements as mode of 

administration, informed consent 

materials, use of advance letters, timing 

and frequencies of contacts; 

• For the PCC initiative, indicate 

whether the instrument (or 

observational measure) is designed for 

use with patients or clinicians, as well 

as a statement indicating whether or not 

the submitter wishes to be 

acknowledged when the instrument is 

published on the NCI Web site. 

In addition, a description of how 

extensively the survey has been fielded 

should also be included in the 

submission materials. Measures that 

have been tested or implemented in just 

one or two research studies would have 

more limited value than those tested or 

implemented more widely, but 

measures will be considered on an 

individual basis when evaluating the 

measures needing further testing as a 

prerequisite to their inclusion in 

CAHPS® or PCC draft and final survey 

tools. 

Submission of copies of existing 

report formats developed to disclose 

findings to consumers and providers is 

desirable, but not required. 

Additionally, information about existing 

database(s) for the instrument(s) 

submitted is helpful, but not required 

for submission. Evidence of meeting the 

validity, reliability, and other criteria 

may be demonstrated through 

submission of peer-reviewed journal 

article(s) or through the best evidence 

available at the time of submission. 

SUPPLEMENTARY INFORMATION: 

Background 

AHRQ is a leader in developing and 

testing instruments for quantitative 

measurement of consumer experience 

within the healthcare system of the 

United States as evidenced by the 

development and widespread use of 

CAHPS® survey products. The 

Consumer Assessment of Healthcare 

Providers and Systems (CAHPS®) 

program is a public-private initiative to 

develop standardized surveys of patient 

experience of care received in 

ambulatory and facility settings. 

Standardization of measures is essential 

for meaningful comparison of 

performance across providers and 

settings. While CAHPS® instruments 

have been highly regarded within the 

industry and provide valuable 

information, until now, no CAHPS®

condition-specific surveys have been 

developed. Use of a standardized 

measurement instrument for cancer care 

will provide several benefits including: 

Comparable information across cancer 

care providers for the public about the 

quality of care; data-based 

recommendations for quality 

improvement efforts and a data base to 

stimulate further research in this area. 

AHRQ, through a collaborative process 

with NCI and other stakeholders, has 

initiated the process for this project. 

The steps to advance this initiative 

are described below: 

• Survey Development and Testing: 

The process by which measures will be 

defined and the most useful instruments 

or measures identified is as follows: 

Instruments submitted will be evaluated 

by the project team in consultation with 

AHRQ and NCI staff to determine if they 

meet high priority or common 

measurement needs and to identify 

whether additional measure 

development is required. Additional 

measure development will be done as 

needed. 

Until the trademarked versions or 

each instrument are available, access to 

and use of draft versions will require 

explicit written permission from AHRQ 

and sharing of testing results with the 

CAHPS® team. testing 

• Implementation Plan: The final 

tools and a description of the survey 

process as well as instructions for 

implementing of the final standardized 

CAHPS® and PCC cancer care 

instruments will be made available at no 

cost to the public on AHRQ and NCI 

Web sites and will include requirements 

and information related to their use in 

future data collections, analysis, and 

public reporting. 

Dated: February 16, 2010. 

Carolyn M. Clancy, 

Director, AHRQ. 

[FR Doc. 2010–4387 Filed 3–3–10; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 75 FR 7489–7490, dated 

February 19, 2010) is amended to reflect 

the establishment of the Office of 

Infectious Diseases, Centers for Disease 

Control and Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: After the mission statement for 

the Centers for Disease Control and 

Prevention (C), insert the following: 

Office of Infectious Diseases (CV). The 

mission of the Office of Infectious 

Diseases (OID) is to lead, promote, and 

facilitate science, programs, and policies 

to reduce the burden of infectious 

diseases in the United States and 

globally. 

Office of the Director (CVA). (1) 

Serves as the principal advisor to the 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 75, No. 42 / Thursday, March 4, 2010 / Notices 9915 

CDC Director on infectious disease 

issues; (2) assists the CDC Director in 

formulating and communicating 

strategic initiatives and policies; (3) 

informs the CDC Director about key 

infectious disease issues; (4) represents 

the CDC Director externally on 

infectious disease issues; (5) provides 

strategic leadership to CDC’s infectious 

disease national centers; (6) develops 

overall strategic directions, sets 

priorities, and promotes science, 

policies, and programs related to 

infectious diseases; (7) ensures that 

agency-wide decisions on resource 

allocation are aligned with infectious 

disease priorities; (8) works with 

infectious disease national centers, 

other CDC centers and offices, and 

public health partners to develop and 

implement infectious disease goals and 

objectives; (9) identifies infectious 

disease issues of public health 

importance and launches strategic 

initiatives to address them, including 

developing shared goals and monitoring 

progress and accomplishments; (10) 

recruits and supports an efficient, 

effective, and vibrant work force, and 

fosters a safe and healthy work 

environment; (11) enhances 

cooperation, collaboration, and 

partnerships across multiple sectors, 

domestically and globally; (12) ensures 

integrity, transparency, and excellence 

in public health science and practice; 

(13) conducts ongoing evaluation and 

adjustment of infectious disease 

activities to ensure optimal effectiveness 

and efficiency; (14) promotes an 

environment that increases synergies 

and efficiencies and reduces duplication 

within CDC’s infectious disease 

programs; and (15) provides direction 

and leadership for external and internal 

program reviews of the infectious 

disease national centers’ initiatives, 

performance, and achievements. 

Influenza Coordination Unit (CVA4). 

The mission of the Influenza 

Coordination Unit (ICU) is to 

synchronize all aspects of CDC’s 

pandemic influenza preparedness and 

response from strategy through 

implementation and evaluation. In 

carrying out its mission, the ICU: (1) 

Serves as the principal advisor to the 

CDC Director and Deputy Director for 

Infectious Diseases on pandemic 

influenza preparedness and response 

activities, assisting the Director and 

Deputy Director for Infectious Diseases 

in formulating and communicating 

strategic pandemic initiatives and 

policies; (2) provides strategic 

leadership for CDC in the areas of 

pandemic preparedness and response, 

including setting priorities and 

promoting science, policies, and 

programs related to pandemic influenza; 

(3) strategically manages a $150+ 

million budget and allocates funds 

across the agency to ensure appropriate 

resources for high priority areas; and (4) 

conducts ongoing evaluation and 

adjustment of pandemic preparedness 

and response activities, in coordination 

with the National Response Framework 

and other emergency preparedness 

guidance, to ensure optimal public 

health effectiveness and efficient use of 

human and fiscal resources. 

Dated: February 23, 2010. 

William P. Nichols, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2010–4391 Filed 3–3–10; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HOMELAND 

SECURITY 

Transportation Security Administration 

[Docket No. TSA–2009–0018] 

Extension of Agency Information 

Collection Activity Under OMB Review: 

Certified Cargo Screening Program 

AGENCY: Transportation Security 

Administration, DHS. 

ACTION: 30-Day notice. 

SUMMARY: This notice announces that 

the Transportation Security 

Administration (TSA) has forwarded the 

Information Collection Request (ICR), 

OMB control number 1652–0053, 

abstracted below to the Office of 

Management and Budget (OMB) for 

renewal in compliance with the 

Paperwork Reduction Act. The ICR 

describes the nature of the information 

collection and its expected burden. TSA 

published a Federal Register notice, 

with a 60-day comment period soliciting 

comments, of the following collection of 

information on November 16, 2009, 74 

FR 58967. TSA has received no 

comments. The collections include: (1) 

Applications from entities that wish to 

become Certified Cargo Screening 

Facilities (CCSF) or operate as a TSAapproved validation firm; (2) personal 

information to allow TSA to conduct 

security threat assessments on key 

individuals employed by the CCSFs and 

validation firms; (3) implementation of 

a standard security program or 

submission of a proposed modified 

security program; (4) information on the 

amount of cargo screened; (5) 

recordkeeping requirements for CCSFs 

and validation firms; and (6) submission 

of validation reports to TSA. TSA is 

seeking the renewal of the ICR for the 

continuation of the program in order to 

secure passenger aircraft carrying cargo 

by the deadlines set out in the 

Implementing Recommendations of the 

9/11 Commission Act of 2007. 

DATES: Send your comments by April 5, 

2010. A comment to OMB is most 

effective if OMB receives it within 30 

days of publication. 

ADDRESSES: Interested persons are 

invited to submit written comments on 

the proposed information collection to 

the Office of Information and Regulatory 

Affairs, Office of Management and 

Budget. Comments should be addressed 

to Desk Officer, Department of 

Homeland Security/TSA, and sent via 

electronic mail to 

oira_submission@omb.eop.gov or faxed 

to (202) 395–6974. 

FOR FURTHER INFORMATION CONTACT: 

Joanna Johnson,, TSA Paperwork 

Reduction Act (PRA) Officer, Office of 

Information Technology (OIT), TSA–11, 

Transportation Security Administration, 

601 South 12th Street, Arlington, VA 

20598–6011; telephone (571) 227–3651; 

e-mail TSAPRA@dhs.gov. 

SUPPLEMENTARY INFORMATION: 

Comments Invited 

In accordance with the Paperwork 

Reduction Act of 1995 (44 U.S.C. 3501 

et seq.), an agency may not conduct or 

sponsor, and a person is not required to 

respond to, a collection of information 

unless it displays a valid OMB control 

number. The ICR documentation is 

available at http://www.reginfo.gov. 

Therefore, in preparation for OMB 

review and approval of the following 

information collection, TSA is soliciting 

comments to— 

(1) Evaluate whether the proposed 

information requirement is necessary for 

the proper performance of the functions 

of the agency, including whether the 

information will have practical utility; 

(2) Evaluate the accuracy of the 

agency’s estimate of the burden; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

(4) Minimize the burden of the 

collection of information on those who 

are to respond, including using 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Information Collection Requirement 

Title: Certified Cargo Screening 

Program. 

Type of Request: Renewal of one 

currently approved collection. 

OMB Control Number: 1652–0053. 

mstockstill on DSKH9S0YB1PROD with NOTICES